

Cystic Fibrosis, Oral

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**

AmeriHealth Caritas Louisiana **1-800-684-5502**

Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**

Healthy Blue **1-844-521-6942**

Louisiana Healthcare Connections **1-888-929-3790**

UnitedHealthcare **1-800-310-6826**

Cystic Fibrosis, Oral

POS Edits	
Elexacaftor/Tezacaftor/Ivacaftor with Ivacaftor (Trikafta®) CL – Additional clinical information (gene mutation, etc.) is required for elexacaftor/tezacaftor/ivacaftor with ivacaftor (Trikafta®). <u>these agents.</u>	
Ivacaftor (Kalydeco®)	CL – Additional clinical information (gene mutation, etc.) is required for ivacaftor (Kalydeco®).
Lumacaftor/ Ivacaftor (Orkambi®)	CL – Additional clinical information (gene mutation, etc.) is required for lumacaftor/ivacaftor (Orkambi®).
Tezacaftor (Symdeko®)	CL – Additional clinical information (gene mutation, etc.) is required for tezacaftor (Symdeko®).

Revision / Date	Implementation Date
Created POS Document	February 2020
Updated age for BH in POS Abbreviations chart / November 2020	January 2021
Added Trikafta® / April 2021	July 2021
<u>Included Bronchitol® / May 2021</u>	<u>July 2021</u>